Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Transgene Reports 2015 Financial Results and Provides Outlook for 2016 (webcast)

20160309 FY 2015 results version FINALE

Published 8 March 2016
Categorized as 2016, Press release

Transgene Announces Participation at Upcoming Investor Events

20160302 March April 2016 IR events ENG

Published 2 March 2016
Categorized as 2016, Press release

Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset

20160203 PR ABL TG SYMPHONY

Published 3 February 2016
Categorized as 2016, Press release

EIB lends EUR 20m to Transgene

20160128 PR transgene BEI final version

Published 28 January 2016
Categorized as 2016, Press release

Transgene Announces Financial Calendar for 2016

20160108 financial calendar_EN ver 1

Published 8 January 2016
Categorized as 2016, Press release

Transgene enters new phase in its strategic development

20160107 Strategic update ENG clean

Published 7 January 2016
Categorized as 2016, Press release

Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer

20160106 Ph 3 pexa vec in HCC trial initiation VER8

Published 6 January 2016
Categorized as 2016, Pexa-Vec, Press release

Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer

20151223_TIME Ph2b Lancet Oncology 2015_PR EN

Published 23 December 2015
Categorized as 2015, Press release, TG4010

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

Elisabeth Quoix, et al. The Lancet Oncology, December 2015, 17: 212–23 – Download the article Publication

Published 18 December 2015
Categorized as -others, 2015, Publication, TG4010

A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates

Stephane Leung-Theung-Long, et al. PLOS One, November 24, 2015 DOI: 10.1371/journal.pone.0143552 – Download the article Publication

Published 24 November 2015
Categorized as -others, 2015, Publication, TB Program

Posts pagination

Newer posts Page 1 … Page 42 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu